4.5 Review

Renshen (Panax ginseng) and Huanglian (Rhizoma Coptidis) For T2DM A protocol of systematic review and meta-analysis of randomized clinical trials

期刊

MEDICINE
卷 100, 期 2, 页码 -

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000023743

关键词

Huanglian (Rhizoma Coptidis); meta-analysis and systematic review; protocol; Renshen (Panax ginseng); T2DM

资金

  1. National Science Foundation of China [81774279]
  2. Key Research and Development Project of Sichuan Province [2018SZ0068]

向作者/读者索取更多资源

Type 2 diabetes mellitus is a global epidemic with serious impact on individuals and society. This study aims to evaluate the effectiveness and safety of ginseng and coptis intervention in the treatment of T2DM, providing valuable evidence for future research.
Introduction: Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by high blood sugar caused by impaired insulin action. With an increasing incidence year by year, it has become a worldwide epidemic. Because of its serious, long-term condition, T2DM has a bad impact on the life and well-being of individuals, families and society. Renshen and Huanglian or compound prescription contain Renshen and Huanglian for treatment of T2DM has already been confirmed. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to carry out systematic evaluation on Renshen and Huanglian and provide effective evidence for further research. Methods and analysis: We will search English databases (PubMed, Embase, Web of Science, Nature, Science on line, the Cochrane Library) and Chinese databases (CNKI, Wan Fang, VIP, Chinese biomedical database), from the establishment of database to October 2020, for randomized controlled trials (RCTs) of ginseng and coptis and the compound containing ginseng and coptis in the treatment of T2DM. Primary outcomes: fasting blood-glucose (FBG), 2 Hours Postprandial Blood Glucose (2hPBG), Glycosylated hemoglobin A1c (HbA1c). Additional outcomes: Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), triglycerides (TG), total serum cholesterol (TC). Two researchers independently extracted the data and evaluated the quality of the included research, and meta-analysis was conducted on the included data using the software of RevMan5.3 and Stata V.12.0. Results: The results of this study will systematically evaluate the effectiveness and safety of Renshen and Huanglian intervention for people with T2DM. Conclusion: The systematic review of this study will summarize the current published evidence of Renshen and Huanglian or compound prescription contain Renshen and Huanglian for the treatment of T2DM, which can further guide the promotion and application of it. Ethics and dissemination: This study is a systematic review; the outcomes are based on the published evidence, so examination and agreement by the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations. Open Science Framework (OSF) registration number: October 18, 2020. osf.io/8gz7c (https://osf.io/8gz7c).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据